Monitoring is Key in Precipio ’s Liquid Biopsy Success

The liquid biopsy market has expanded greatly in the past few years. From billion-dollar financings to highly publicized spinouts – the space has managed to attract quite a bit of attention and change the dynamic of diagnostics. Earlier this week, Roche made a big play in the space by acquiring the remaining shares of Foundation Medicine for $2.4 billion. Precipio is hoping to make its own impact in liquid biopsy and said it is focused on the monitoring segment of the market. The New Haven, CT-based company is about a year removed from merging with Transgenomics. The transaction also helped Precipio become a public company – although that wasn’t the main reason for the merger, said Ilan Danieli, CEO of the combined firm. “What I find is an interesting view is that people see our transaction and assume that we wanted to become public,” Danieli told MD+DI. “They say we did a merger with [Transgenomics] and oh-by-the way- got this technology, but it’s actually the reverse. What drove the transaction is the technology.” Last month, Precipio said it launched two additional ICEme kits using its ICE-COLD PCR liquid biopsy technology. The new RUO kits enable the detection of mutations in KRAS Exons 2 & 3, which include important predictive and prognostic biomarkers, and are available on both qPCR and Sanger molecular diagnostic platforms. The ICP kits will be priced at about $100 per specimen, a fraction of competing liquid biopsy tests. Laboratories running ICP c...
Source: MDDI - Category: Medical Devices Authors: Tags: IVD Testing Source Type: news